Quarterly beat puts the spotlight on Attruby BridgeBio Pharma (BBIO) just delivered quarterly revenue that topped expectations, powered by stronger than anticipated U.S. sales of its cardiomyopathy ...

Investors in BridgeBio Pharma Inc (Symbol: BBIO) saw new options become available this week, for the February 2024 expiration. One of the key data points that goes into the price an option buyer is ...

BridgeBio Pharma (BBIO) has surged 145% over the past year, reaching an all-time high of $75.10. ・BBIO maintains a strong ...

Fintel reports that on December 11, 2025, Bernstein initiated coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Outperform ...

Investors in BridgeBio Pharma Inc (Symbol: BBIO) saw new options become available this week, for the May 2026 expiration. One of the key data points that goes into the price an option buyer is willing ...

We recently published an article titled 10 Firms Post Impressive Gains on Tuesday. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other ...

We recently published an article titled Massive Sell-Offs Just Hit These 10 Stocks Today. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the ...

BridgeBio Pharma, Inc. (BBIO) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where BridgeBio Pharma (NASDAQ:BBIO) stands against the other stocks.

BridgeBio Pharma Inc (NASDAQ:BBIO) announced the presentation of detailed results from its Phase 3 ATTRibute-CM study of acoramidis for ATTR-CM at the European Society of Cardiology Congress 2023.